|
|
|
Volumn 26, Issue 5 SUPPL. 17, 1999, Pages 34-38
|
|
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BICALUTAMIDE;
DOCETAXEL;
ESTRAMUSTINE;
KETOCONAZOLE;
PROSTATE SPECIFIC ANTIGEN;
RETINOIC ACID;
VALSPODAR;
ADULT;
AGED;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RESISTANCE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
FATIGUE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
LEUKOPENIA;
MALE;
METASTASIS;
ORAL DRUG ADMINISTRATION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
REVIEW;
THROMBOCYTOPENIA;
THROMBOEMBOLISM;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CLINICAL TRIALS, PHASE I;
CLINICAL TRIALS, PHASE II;
ESTRAMUSTINE;
HUMANS;
MALE;
NEOPLASM METASTASIS;
NEOPLASMS, HORMONE-DEPENDENT;
PACLITAXEL;
PROSTATIC NEOPLASMS;
TAXOIDS;
|
|
EID: 0033406880
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (29)
|
|
References (21)
|
